Treat with foresight
namd

nAMD

Unsurpassed and sustained vision gains with proactive extended dosing1,2

2X

Long-lasting VEGF-A suppression

Up to 2x longer than ranibizumab3-5

proactive Extended dosing

Proactive extended dosing

By Week 96 in the ALTAIR study:

  • Up to 60% of patients reached an injection interval of ≥12 weeks1,2
  • Up to 46% of patients reached an injection interval of 16 weeks2
Decreased injection frequency

Decreased injection frequency

Achieve sustained VA gains with as few as 3 injections in Year 2 1

EYLEA®: YOUR CHOICE FOR FOR PROACTIVE TREAT AND EXTEND UP TO Q161

Sustained VEGF supression with EYLEA1

Mean Duration

Mean duration of VEGF-A suppression with EYLEA:67+/-14 days

Mean duration of VEGF-A suppression with ranibizumab 34+/-5days

 Definite VEGF suppression

 Uncertain suppression status

Uncertain end of suppression

 

Long-lasting anti-VEGF activity upto 2x longer than a ranibizumab (P<0.0001)4,5

VA GAINS MAINTAINED AT YEAR 2 WITH PROACTIVE EXTENDED DOSING2

Q12 and beyond: VA gains observed in Year 1 and Year 2 of ALTAIR1,2

Mean number of injections at 96 weeks for both groups: 10.4 injections2

ACHIEVE UNSURPASSED AND SUSTAINED VA GAINS WITH EYLEA

Treat and extend patients up to Q161,2,6

    Proportion of patients
    Proportion of patients
    • Proportion of patients achieving 12-week dosing at 96 weeks
    • Proportion of patients achieving 16-week dosing at 96 weeks
    Proportion of patients
    Proportion of patients
    • Proportion of patients achieving 12-week dosing at 96 weeks
    • Proportion of patients achieving 16-week dosing at 96 weeks

    Achieve sustained VA gains with as few as 3 injections in Year 2 when proactive T&E is used with EYLEA1,2

    Dosing
    MOA

    References:

    • EYLEA® (aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG.
    • Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; for ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial [published online ahead of print February 3, 2020]. Adv Ther. doi: 10.1007/s12325-020-01236-x.
    • Muether PS, Hermann MM, Dröge K, Kirchhof B, Fauser S. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol. 2013;156:989-993.
    • Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;100:1494-1498.
    • Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158:532-536.
    • Richard G, Monés J, Wolf S, et al. Scheduled versus pro re nata dosing in the VIEW trials. Ophthalmology. 2015;122:2497-2503.
    • Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap,ranibizumab and bevacizumab. Angiogenesis. 2012;15;171-185.

    This website contains information on EYLEA® (aflibercept solution for injection) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission. It is intended to provide information to an international audience outside the USA and UK. In countries outside the EU the local Product Information applies.

    PP-EYL-ALL-0513-1. Last updated on 29/02/2020